Expert Ratings for Quest Diagnostics
Portfolio Pulse from Benzinga Insights
Over the last quarter, Quest Diagnostics (NYSE:DGX) received 4 indifferent analyst ratings with no bullish or bearish positions. The average 12-month price target for DGX is $137.25, with a high of $149.00 and a low of $130.00. This target has decreased by 2.83% from the previous target of $141.25. Analyst ratings are provided quarterly and are based on financial analysis and insider information, but they are subject to human error.
November 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics received 4 indifferent analyst ratings in the past quarter with an average price target of $137.25, reflecting a 2.83% decrease from the previous target.
The indifferent analyst ratings suggest a neutral short-term impact on DGX's stock price. The slight decrease in the average price target may not significantly influence investor sentiment as it does not indicate a major shift in company valuation or performance expectations. The confidence level is high due to the direct correlation between analyst ratings and stock performance, although the importance is not at the maximum because analyst ratings are just one of many factors investors consider.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100